ERBB2 and breast cancer: Thus, ferroptosis inducers could potentially improve the existing BC treatments, e.g., by being used together with trastuzumab to delay the onset of BC trastuzumab resistance and/or together with ErbB2-targeted drugs utilized for trastuzumab-resistant BC treatment.